Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis.

@article{Surrey2002EffectOP,
  title={Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis.},
  author={Eric S. Surrey and Kaylen M. Silverberg and Mark W. Surrey and William B Schoolcraft},
  journal={Fertility and sterility},
  year={2002},
  volume={78 4},
  pages={
          699-704
        }
}

Figures and Tables from this paper

Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer

It was concluded that use of long-acting GnRH-a can effectively reduce the transplant cancellation rate and improve the clinical pregnancy rate of the fresh cycle.

Long-Acting GnRH Agonist Improves IVF Outcomes of Young Patients with Diminished Ovarian Reserve by Increasing Endometrial Receptivity.

This first time that the benefit of long-acting GnRH agonist long protocol in follicular phase in young DOR patients has been reported, it can increase endometrial receptivity, reduce cycle cancellation rate and improve IVF cycle clinical outcomes for these patients compared with mild stimulation and GnRH antagonist protocols.

Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial

It is indicated that Dienogest is a suitable and safe substitute for GnRHa pretreatment in endometriosis patients and has a lower cost of treatment, lower side effects, and higher tolerability scores.

Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis.

This systematic review supersedes the previous Cochrane Review on this topic and aims to determine the effectiveness and safety of long-term gonadotrophin-releasing hormone (GnRH) agonist therapy (minimum 3 months) versus no pretreatment or other pretreatment modalities before standard in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) in women with endometriosis.

Pituitary suppression before frozen embryo transfer is beneficial for patients suffering from idiopathic repeated implantation failure

The results showed that hormonally controlled endometrial preparation with prior GnRHa suppression could be used for patients who had experienced repeated failures of IVF treatment despite having morphologically optimal embryos, and the treatment may help increase the receptivity of the endometrium in these patients.

Comparison of Ovulation Induction Protocols After Endometrioma Resection

A long GnRH-a protocol may lead to a higher number of embryos that can be cryopreserved, providing the possibility of additional embryo transfers without having to go through the process of ovarian stimulation again.
...

References

SHOWING 1-10 OF 30 REFERENCES

The value of pre-treatment with gonadotrophin releasing hormone (GnRH) analogue in IVF-ET therapy of severe endometriosis.

Following GnRH analogue treatment of moderate and severe endometriosis, a significantly higher number of oocytes were recovered and more embryos were transferred and significantly higher clinical pregnancy rates per cycle were achieved.

Pretreatment with gonadotrophin releasing hormone (GnRH) analogue prior to in vitro fertilisation for patients with endometriosis.

High rates of pregnancy after long-term down-regulation of women with severe endometriosis.

Results of IVF in patients with endometriosis: the severity of the disease does not affect outcome, or the incidence of miscarriage.

More than 140 patients with endometriosis underwent 182 cycles of IVF using gonadotrophin-releasing hormone analogues (GnRHa) and the fertilization rate was significantly lower in group 1; no difference was observed in the other three groups.